|
|
PRECAUTIONS
Metroprolol succinate CAS NO 98418-47-4
Metoprolol Succinate extended-release tablets should be used with caution in
patients with impaired hepatic function. In patients with pheochromocytoma,
an alpha-blocking agent should be initiated prior to the use of any
beta-blocking agent.
Worsening cardiac failure may occur during up-titration of Metoprolol
Succinate extended-release tablets. If such symptoms occur, diuretics should
be increased and the dose of Metoprolol Succinate extended-release tablets
should not be advanced until clinical stability is restored. It may be
necessary to lower the dose of Metoprolol Succinate extended-release tablets
or temporarily discontinue it. Such episodes do not preclude subsequent
successful titration of Metoprolol Succinate extended-release tablets.
Patients should be advised to take Metoprolol Succinate extended-release
tablets regularly and continuously, as directed, preferably with or
immediately following meals. If a dose should be missed, the patient should
take only the next scheduled dose (without doubling it). Patients should not
interrupt or discontinue Metoprolol Succinate extended-release tablets
without consulting the physician.
Patients should be advised
(1) to avoid operating automobiles and machinery or engaging in other tasks
requiring alertness until the patient's response to therapy with Metoprolol
Succinate extended-release tablets has been determined;
(2) to contact the physician if any difficulty in breathing occurs;
(3) to inform the physician or dentist before any type of surgery that he or
she is taking Metoprolol Succinate extended-release tablets.
Heart failure patients should be advised to consult their physician if they
experience signs or symptoms of worsening heart failure such as weight gain
or increasing shortness of breath.
|
©
2004 - 2009
Taj Pharmaceuticals Limited
. All rights reserved
India